Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Inovio Pharmaceuticals Inc (INO) vs Envista Holdings Corporation Common Stock (NVST) Price & Performance

Inovio Pharmaceuticals IncTrade
Envista Holdings Corporation Common StockTrade

Price performance (Past 24H)

Key statistics

Inovio Pharmaceuticals Inc vs Envista Holdings Corporation Common Stock — how do they compare? Inovio Pharmaceuticals Inc trades at $0.98 (market cap $101.95M), while Envista Holdings Corporation Common Stock trades at $22.57 (market cap $3.67B). The key difference: Envista Holdings Corporation Common Stock is far larger — about 36× Inovio Pharmaceuticals Inc's market cap, and Envista Holdings Corporation Common Stock is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Envista Holdings Corporation Common Stock for 0 Days on average.

INONVST
Market Cap
$101.95M$3.67B
Volume
2,985,8471,988,435
Sector
HealthHealth
52-Week High
$2.60$30.26
52-Week Low
$0.66$18.95
Typical Hold Time
43 Days0 Days
Enterprise Value
$73.28M$4.13B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals (INO) trades at $0.9982, down 9.67% in the last session, with a bearish technical signal from moving averages. The company shows minimal revenue of $65,340 but has beaten EPS estimates for three consecutive quarters. Key focus remains on the FDA's October 30, 2026 PDUFA decision for INO-3107, its lead candidate for recurrent respiratory papillomatosis. Analyst consensus is bullish with a $2.75 price target, though financials reveal significant losses with a -130,000% net income margin and negative cash flow from operations.

The investment case hinges on regulatory approval of INO-3107, offering substantial upside if successful. However, high cash burn, persistent losses, and dependence on financing pose severe risks. With 59% of analysts rating Buy, the stock presents a high-risk, high-reward opportunity suitable only for speculative investors comfortable with binary outcomes.

Envista Holdings Corporation Common Stock

No Aura AI signal available yet.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

INO
97% Buy3% Sell
Avg holding period · 43 Days
NVST
100% Buy0% Sell
Avg holding period · 0 Days

About Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.

Read more on INO →

About Envista Holdings Corporation Common Stock

Envista Holdings Corporation is a global dental products company that develops, manufactures, and markets dental implants, orthodontic systems, and other consumables and equipment for dental professionals worldwide.

Read more on NVST →